Category 1 vs. Category 2 Peptides: A Plain-English Patient Guide to What These FDA Labels Actually Mean

If you have searched for peptide therapy recently, you have probably hit a wall of regulatory language — category 1 category 2 peptides explained, FDA bulk drug substances, compounding eligibility. The terms are real, and they directly affect what a licensed clinic can prescribe for you today.

Here is the short answer: Category 1 means a compounding pharmacy can legally prepare the peptide with a valid prescription. Category 2 means it cannot — at least not yet. Everything below unpacks what that actually means, why it changed, and what it means for your access to care.

What Are FDA Bulk Drug Substance Categories?

The FDA bulk drug substance categories are a classification system the agency created to manage peptide compounding eligibility while formal approval processes catch up to clinical demand.

Under Section 503A of the Federal Food, Drug, and Cosmetic Act (FD&C Act), a traditional compounding pharmacy — what most patients think of as their local or mail-order specialty pharmacy — may only prepare drugs using bulk substances that meet one of three conditions:

1. The substance complies with a United States Pharmacopeia (USP) or National Formulary (NF) monograph.
2. The substance is an active ingredient in an FDA-approved drug.
3. The substance appears on the FDA's 503A Bulks List.1

Most peptides used in metabolic and hormonal health do not have USP monographs. Most are not active ingredients in FDA-approved drugs. That sends them directly to the third pathway — the 503A Bulks List — and specifically to the category framework the FDA built to manage that list while it evaluates each substance.2

Category 1 vs. Category 2: The Core Distinction

The difference is simple. The consequence is significant.

Category 1 is not FDA approval. It is enforcement discretion — the agency's formal signal that it will not pursue a compounder preparing that substance, provided all other legal conditions are met. That distinction matters. A Category 1 peptide is still an unapproved drug. It still requires a prescription. It still requires a licensed, qualified compounding pharmacy.3

Category 2 is also not a permanent ban. It is a classification indicating the FDA identified safety concerns sufficient to remove the substance from the compounding pathway — until those concerns are resolved through the formal review process.4

How Did the Category System Come to Be?

Peptide compounding eligibility did not always look like this. Understanding the timeline helps patients make sense of the current landscape.

2013: The Drug Quality and Security Act creates Sections 503A and 503B of the FD&C Act, establishing a formal framework for compounding pharmacies and outsourcing facilities respectively.5

Pre-2023: Many peptides were available through compounding pharmacies with limited formal regulatory structure. Demand grew rapidly — driven by interest in body composition, metabolic health, longevity, and hormonal function.

September 2023: The FDA moved 17 widely-used peptides onto its Category 2 list, citing concerns about immunogenicity, manufacturing impurity risks, and limited human trial data.6 Practically overnight, substances like BPC-157, CJC-1295, ipamorelin, TB-500, Thymosin Alpha-1, AOD-9604, Selank, Semax, and others became unavailable through licensed compounding channels.

January 2025: The FDA released updated interim guidance formally codifying the Category 1/2/3 framework — and eliminating Category 3.7 Category 1 substances remained available under enforcement discretion. Former Category 2 and 3 substances remained prohibited from compounding.

February–April 2026: A significant policy shift began. HHS Secretary Robert F. Kennedy Jr. publicly signalled that approximately 14 of the 19 restricted peptides were expected to move back toward Category 1 status.8 Nominations for those 12 peptides were formally withdrawn by nominators, triggering their removal from Category 2 effective April 23, 2026.9

July 23–24, 2026: The FDA's Pharmacy Compounding Advisory Committee (PCAC) is scheduled to convene to formally evaluate whether these peptides should be added to the 503A Bulks List — the step that would permanently authorise their compounding.10

This is a fluid regulatory environment. The rules in effect today may differ from the rules in effect when you read this. That is precisely why working with a clinician who actively tracks these updates matters.

Category 1 vs. Category 2 Peptides Explained: Which Substances Are Affected?

Here is where category 1 category 2 peptides explained becomes practically relevant for patients.

Peptides that were on Category 2 and are now under PCAC review (removed from Category 2 as of April 2026):11

• BPC-157 — Studied for gut healing, musculoskeletal repair, tendon recovery, and anti-inflammatory effects. One of the most prescribed peptides before the 2023 restriction.
• Thymosin Alpha-1 — An immune-modulating peptide approved as a pharmaceutical in over 30 countries for hepatitis B, hepatitis C, and oncology support applications.
• TB-500 (Thymosin Beta-4 Fragment) — Studied for tissue repair, wound healing, and inflammation reduction.
• CJC-1295 — A growth hormone-releasing hormone (GHRH) analogue that stimulates natural growth hormone production. Relevant to metabolic health, body composition, and sleep quality.
• Ipamorelin — A selective growth hormone secretagogue, frequently used alongside CJC-1295 in clinical protocols targeting metabolic restoration in men over 40.
• AOD-9604 — A growth hormone fragment studied for its fat-loss properties without the systemic side effects of full HGH. Relevant to visceral fat and body composition.
• GHK-Cu (injectable form) — A copper peptide with applications in skin health and anti-aging. Note: the topical form remains on Category 1.
• Selank and Semax — Nootropic peptides being evaluated for cognitive function, anxiety, and neuroprotective effects. See Meto's deep-dive on Semax and Selank cognitive peptides.
• MOTS-c — A mitochondrial-derived peptide studied for insulin sensitivity and metabolic function. Covered in detail in our mitochondrial peptides and insulin resistance guide.
• KPV — A tripeptide studied for anti-inflammatory and gut health applications.

Important caveat: Removal from Category 2 does not automatically mean these peptides are now Category 1. As of mid-2026, they exist in a transitional state. The PCAC July 2026 meetings will determine whether they receive formal placement on the 503A Bulks List. Your clinician should confirm current status before initiating any protocol.

503A vs. 503B: The Pharmacy Difference That Affects Your Access

Understanding peptide scheduling explained also means understanding the two types of compounding facilities that sit behind every prescription.

Section 503A pharmacies are traditional compounding pharmacies. They:

• Prepare medications based on individual patient-specific prescriptions
• Are primarily regulated by state boards of pharmacy
• Cannot compound large batches for general stock
• Must have a valid prescriber-patient relationship in place before filling12

Section 503B outsourcing facilities are FDA-registered and operate under Current Good Manufacturing Practice (cGMP) standards — closer to pharmaceutical manufacturing. They:

• Can prepare large batches without patient-specific prescriptions for distribution to healthcare facilities
• Are subject to FDA inspection
• Have more stringent quality controls, stability testing, and documentation requirements
• Can distribute more freely across state lines13

For most patients, the 503A list is the gating document. If a peptide is in Category 1 on that list, a licensed 503A pharmacy can prepare it. If it is not, no legitimate compounding pathway exists through a 503A facility.

The 503B list operates separately. Some substances available to 503B outsourcing facilities differ from 503A. This is why a prescribing clinician needs to understand which facility type their pharmacy of choice operates under — and what is currently permissible within each framework.

What Category 2 Designation Does NOT Mean

Several misconceptions circulate in patient communities. These are worth addressing directly.

It does not mean the peptide is dangerous. Category 2 means the FDA identified potential safety concerns sufficient to exclude it from compounding enforcement discretion — not that the compound is toxic or causes harm. Many Category 2 peptides have decades of preclinical data and are used clinically in other countries.14

It does not mean the peptide is illegal to possess. Category designations govern compounding pharmacy eligibility. They do not constitute criminal prohibitions on possession for personal use.

It does not mean gray-market alternatives are a reasonable substitute. When legitimate compounding was restricted in 2023, demand shifted toward unregulated "research use only" sources. Independent testing of these products has found significant contamination, mislabeling, and in some cases no detectable peptide at all.15 Category classification exists precisely to ensure that when peptides are prescribed, they come from facilities with quality controls in place.

It does not mean the status is permanent. The current reclassification activity demonstrates this clearly. The regulatory framework is designed to evolve as evidence accumulates and nominations are reviewed.

What the PCAC July 2026 Meeting Means for Patients

The Pharmacy Compounding Advisory Committee meetings scheduled for July 23–24, 2026 are the most significant regulatory event for peptide therapy access in several years.16

The committee is expected to evaluate whether specific peptides — including several that drove the most clinical interest before 2023 — should be formally added to the 503A Bulks List.

A formal addition would:

1. Create a durable, stable legal pathway for compounding (not just enforcement discretion)
2. Allow licensed 503A pharmacies to prepare these peptides with physician prescriptions
3. Reduce the legal ambiguity that has complicated prescribing since 2023

What the PCAC decision will not do:

• Approve these peptides as FDA-regulated drugs
• Remove the prescription requirement
• Validate unregulated sources

A second PCAC meeting is also scheduled before the end of February 2027, meaning the review process will continue beyond the July session.17

How This Affects Patients Pursuing Metabolic and Hormonal Peptide Therapy

If you are exploring peptide therapy for weight management, insulin resistance, hormonal support, or metabolic restoration, the category framework affects you in three specific ways.

Access timing. Some peptides you may have read about — including popular protocols involving CJC-1295/ipamorelin or BPC-157 — are currently in regulatory transition. A clinician who tracks these developments can tell you exactly what is available today and when access is likely to expand.

Source integrity. Category 1 status, combined with a licensed 503A or 503B pharmacy, is your quality assurance signal. It does not guarantee perfection, but it guarantees regulatory oversight, sterile compounding environments, and Certificates of Analysis for each batch. Gray-market sources offer none of these.

Prescription requirement. Regardless of category, no compounded peptide is available without a valid prescription from a licensed provider who has evaluated you. That prescription requirement exists for a reason. Peptides interact with hormonal and metabolic systems. Dosing, cycling, and monitoring matter. If you are considering therapies involving peptides related to growth hormone signalling or mitochondrial function, clinical oversight is not optional — it is the difference between therapeutic benefit and adverse outcomes.

Conclusion

The category 1 category 2 peptides explained framework is, at its core, a quality and safety gating system. Category 1 means a compounding pathway exists — under physician supervision, through a licensed pharmacy. Category 2 means that pathway is closed until the FDA's review process advances.

The landscape is actively shifting. The 2026 reclassification movement represents the most significant expansion of peptide compounding access in three years. But "shifting" is not the same as "resolved." Regulations are nuanced, facility-specific, and change on timelines that do not always align with patient needs.

The right approach is straightforward: work with a clinician who is actively tracking every update, can prescribe appropriately within the current framework, and will adjust your protocol as regulatory access expands.

Work With a Meto Clinician Who Stays Current on Every Regulatory Update

Meto clinicians follow FDA bulk drug substance categories in real time. When peptide access expands, they know. When status changes, they adjust.

If you are exploring peptide therapy as part of a broader metabolic or hormonal health plan, start with your Meto assessment today. Your clinician will review your history, your goals, and the current regulatory landscape — and design a protocol that is both clinically sound and fully compliant.

Get started with Meto →

Frequently Asked Questions

What is the difference between Category 1 and Category 2 peptides?

Category 1 peptides have been reviewed by the FDA and determined not to present significant safety risks — compounding pharmacies can prepare them under enforcement discretion with a valid prescription. Category 2 peptides have been flagged for potential safety concerns and are not currently eligible for compounding under Section 503A. The categories exist within an interim framework; status can change as the FDA's review advances.

Does Category 1 mean a peptide is FDA-approved?

No. Category 1 means the FDA does not currently intend to take enforcement action against a licensed compounder preparing that substance, provided all other legal conditions are met. The peptide remains an unapproved drug. It still requires a prescription, physician oversight, and a licensed compounding pharmacy. It is not available over the counter.

Can I still access peptides that were previously on Category 2?

Possibly, depending on current status. As of April 2026, 12 peptides were removed from Category 2 following the withdrawal of their nominations. However, removal from Category 2 does not automatically make them available — the FDA's Pharmacy Compounding Advisory Committee (PCAC) must formally evaluate them before they can be placed on the 503A Bulks List. Your clinician should confirm the current status of any specific peptide before starting a protocol.

What is the PCAC, and why does the July 2026 meeting matter?

The PCAC (Pharmacy Compounding Advisory Committee) is the FDA's expert advisory body that evaluates nominations for the 503A Bulks List. The July 23–24, 2026 meeting is scheduled to review several peptides previously restricted under Category 2. A positive recommendation from the PCAC would advance those peptides toward formal inclusion on the 503A Bulks List — creating a durable, stable compounding pathway for licensed pharmacies. It is the most consequential peptide regulatory event since the 2023 restrictions.

Is it safe to buy peptides from online "research use only" sources?

No. When licensed compounding pathways were restricted in 2023, demand shifted to unregulated gray-market sources. Independent testing has found contamination, mislabelling, and products with no detectable active ingredient in a significant percentage of samples. The category framework, combined with licensed 503A and 503B pharmacies, exists specifically to ensure quality and safety controls. Physician-prescribed peptides from licensed compounders are the only supply chain with regulatory oversight and batch-specific quality testing.

Do compounded peptides require a prescription?

Yes, always. Regardless of FDA category, every compounded peptide requires a valid prescription from a licensed provider who has an established relationship with the patient. There are no exceptions within the legal framework. This requirement is not a bureaucratic formality — it ensures appropriate dosing, clinical monitoring, and accountability for outcomes.